CTMX Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q3

FY2025Q4

FY2026Q1

7.51M

-80.27%

-0.050

-170.84%

6.67M

-86.91%

-0.083

-136.17%

14.79M

-20.73%

-0.100

-137.04%

Estimates Revision

The market is revising Downward the revenue expectations for CytomX Therapeutics, Inc. (CTMX) for FY2025, with the revenue forecasts being adjusted by -0.06% over the past three months. During the same period, the stock price has changed by 29.46%.

Revenue Estimates for FY2025

Revise Downward

-0.06%

In Past 3 Month

EPS Estimates for FY2025

No Change

0.00%

In Past 3 Month

Stock Price

Go Up

+29.46%

In Past 3 Month

7 Analyst Rating

Wall Street analysts forecast CTMX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CTMX is 6.50 USD with a low forecast of 3.50 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

6 Buy

1 Hold

0 Sell

Strong Buy

Current: 0.000

Low

3.50

Averages

6.50

High

10.00

Current: 0.000

Low

3.50

Averages

6.50

High

10.00

H.C. Wainwright

Mitchell Kapoor

Buy

maintain

$5 -> $10

2025-11-11

Reason

H.C. Wainwright

Mitchell Kapoor

Price Target

$5 -> $10

2025-11-11

maintain

Buy

Reason

H.C. Wainwright analyst Mitchell Kapoor raised the firm's price target on CytomX Therapeutics to $10 from $5 and keeps a Buy rating on the shares. The firm says "strong" CX-2051 trial demand and expansion of enrollment to 100 patients should provide a stronger signal for an approval path.

Piper Sandler

NULL -> Overweight

maintain

2025-11-10

Reason

Piper Sandler

Price Target

2025-11-10

maintain

NULL -> Overweight

Reason

Piper Sandler raised the firm's price target on CytomX Therapeutics to $6.50 from $5 and keeps an Overweight rating on the shares. At SITC, CytomX presented Phase I data on Probody masked IFNalpha2b CX-801 in melanoma and preclinical data on Probody CDH3 T-cell engager CX-908. CytomX will present Phase I CX-801 data in combination with KEYTRUDA in advanced melanoma patients next year. Initial Phase I data on Probody masked EpCAM ADC CX-2051 showed doses of 7.2-10mg/kg achieved an impressive 28% ORR, 94% DCR and preliminary mPFS of 5.8 months in 3rd-line+ metastatic colorectal cancer.

Barclays

Etzer Darout

maintain

2025-10-21

Reason

Barclays

Etzer Darout

Price Target

2025-10-21

maintain

Reason

Barclays analyst Etzer Darout raised the firm's price target on CytomX Therapeutics to $6 from $3.50 and keeps an Overweight rating on the shares. The company's data in late-line colorectal cancer compares favorably to peers, the analyst tells investors in a research note.

Cantor Fitzgerald

NULL -> Overweight

initiated

2025-09-22

Reason

Cantor Fitzgerald

Price Target

2025-09-22

initiated

NULL -> Overweight

Reason

Cantor Fitzgerald initiated coverage of CytomX Therapeutics with an Overweight rating and $6 price target.

Cantor Fitzgerald

Overweight

initiated

2025-09-22

Reason

Cantor Fitzgerald

Price Target

2025-09-22

initiated

Overweight

Reason

Cantor Fitzgerald initiated coverage of CytomX Therapeutics with an Overweight rating and $6 price target. CytomX may have a real contender on its hands with CX-051, a masked epithelial cell adhesion molecule antibody-drug conjugate, and one it can build a franchise around, the analyst tells investors in a research note. Cantor likes the setup, saying that if CX-2051 delivers, CytomX owns a first-in-class space with blockbuster potential in colorectal cancer, and optionality well beyond that.

Barclays

initiated

$3.50

2025-09-16

Reason

Barclays

Price Target

$3.50

2025-09-16

initiated

Reason

Barclays initiated coverage of CytomX Therapeutics with an Overweight rating and $3.50 price target.

Valuation Metrics

The current forward P/E ratio for CytomX Therapeutics Inc (CTMX.O) is -11.78, compared to its 5-year average forward P/E of 13.14. For a more detailed relative valuation and DCF analysis to assess CytomX Therapeutics Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

13.14

Current PE

-11.78

Overvalued PE

84.00

Undervalued PE

-57.72

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-0.69

Current EV/EBITDA

-8.76

Overvalued EV/EBITDA

10.51

Undervalued EV/EBITDA

-11.89

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

3.73

Current PS

21.33

Overvalued PS

7.96

Undervalued PS

-0.50

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

N/A

ROIC

Trading Trends

Insider

Insiders areSelling! The selling amount has increased 359.35% over the last month.

Sold

Bought

Hedge Fund

Hedge Funds areBuying! The buying amount has increased 1979% over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders areSelling! The selling amount has increased 359.35% over the last month.

Sold

Bought

CTMX News & Events

Events Timeline

No data

News

2.0

2025-12-18Benzinga

Birkenstock, Insmed, and Other Major Stocks Decline in Thursday's Pre-Market Trading

6.5

2025-11-22Yahoo Finance

Analysts Discuss the Evolving CytomX Narrative Following Recent Clinical Progress and Increased Price Target

4.0

2025-11-11Benzinga

HC Wainwright & Co. Reaffirms Buy Rating for CytomX Therapeutics and Increases Price Target to $10

People Also Watch

Frequently Asked Questions

What is CytomX Therapeutics Inc (CTMX) stock price today?

The current price of CTMX is 4.35 USD — it has increased 2.11 % in the last trading day.

What is CytomX Therapeutics Inc (CTMX)'s business?

CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company. The Company is focused on developing conditionally activated, masked biologics designed to be localized to the tumor microenvironment. The Company is developing a pipeline of localized biologics, through its PROBODY therapeutic platform. Its pipeline comprises therapeutic candidates across multiple treatment modalities, including ADCs, T-cell engagers, and immune modulators such as cytokines. Its clinical-stage pipeline includes CX-2051, CX-904 and CX-801. CX-2051 is a masked, conditionally activated ADC directed toward EpCAM, armed with a topoisomerase-1 inhibitor payload. CX-904 is a masked, conditionally activated T-cell-engaging bispecific antibody targeting the EGFR on tumor cells and the CD3 receptor on T cells. CX-801 is a masked interferon alpha-2b PROBODY cytokine with broad potential applicability in traditionally immuno-oncology-sensitive as well as insensitive (cold) tumors.

What is the price predicton of CTMX Stock?

What is CytomX Therapeutics Inc (CTMX)'s revenue for the last quarter?

CytomX Therapeutics Inc revenue for the last quarter amounts to 5.96M USD, decreased -82.16 % YoY.

What is CytomX Therapeutics Inc (CTMX)'s earnings per share (EPS) for the last quarter?

CytomX Therapeutics Inc. EPS for the last quarter amounts to -0.09 USD, decreased -228.57 % YoY.

What changes have occurred in the market's expectations for CytomX Therapeutics Inc (CTMX)'s fundamentals?

How many employees does CytomX Therapeutics Inc (CTMX). have?

CytomX Therapeutics Inc (CTMX) has 119 emplpoyees as of January 11 2026.

What is CytomX Therapeutics Inc (CTMX) market cap?

Today CTMX has the market capitalization of 737.04M USD.